Effect of α1-acidic glycoprotein in the ascitic fluid of cancer patients on human NK cells: Selective suppression of interferon-induced NK activation

Inflammation

Volumn 23, Issue 2, 1999, Pages 117-129

  Aso, Hisashi ^a   Tamura, Keiji ^b   Rose, Michael T ^a   Tomioka, Yoshihisa ^c   Mizugaki, Michinao ^c   Ishida, Nakao ^d  

^a NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^b Saikin Kagaku Institute Co Ltd   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d Center for Immunotherapy against Cancer   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; INTERFERON; OROSOMUCOID; RECOMBINANT ALPHA INTERFERON A; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ARTICLE; ASCITES FLUID; CANCER PATIENT; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MONOCYTE; NATURAL KILLER CELL;

EID: 0032896798     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020236927814     Document Type: Article

References (34)

1. 1. Schmid, K. 1975. α1-Acid glycoprotein, In: Putnam, F. W. (editor), The plasma proteins, Vol. 1, Academic Press, New York, pp. 183.
2. 1H-NMR spectroscopy and permethylation analysis. Biochemistry 17:5206.
3. 3. Bacchus, H. 1975. Serum glycoprotein in cancer. Prog. Clin. Pathol. 6:111.
4. 4. Durand, G. 1989. Glycan variants of human α1-acid glycoprotein modulate the biology of macrophages. Evidence that a concanavalin A-unreactive variant is involved in the production of an interleukin 1 inhibitor. Prog. Clin. Biol. Res. 300:247.
5. 5. Kremer, J. M. H., J. Wilting, and L. H. M. Janssen. 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40:1.
6. 6. Costello, M., B. A. Fiedel, and H. Gewurz. 1979. Inhibition of platelet aggregation by native and desialised alpha-1 acid glycoprotein. Nature 281:677.
7. 7. Laine E., R. Couderc, M. Roch-Arveiller, M. P. Vasson, J. P. Giroud, and D. Raichvarg. 1990. Modulation of human polymorphonuclear neutrophil functions by α1-acid glycoprotein. Inflammation 14:1.
8. 8. Chiu, K., R. Mortensen, A. Osmand, and M. Gewurz. 1977. Interactions of alpha 1-acid glycoprotein with the immune system. Immunology 32:997.
9. 9. Bennett, M., and K. Schmid. 1980. Immunosuppression by human plasma α1-acid glycoprotein: Importance of the carbohydrate moiety. Proc. Natl. Acad. Sci. U.S.A. 77:6109.
10. 10. Cheresh, D., D. Hynes, and J. Distasio. 1984. Interaction of an acute phase reactant, α1-acid glycoprotein (orosomucoid), with the lymphoid cell surface: a model for non-specific immune suppression. Immunology 51:541.
11. 11. Singh, V. K. 1989. Immune function studies of alpha-1-acid glycoprotein. Prog. Clin. Biol. Res. 300:283.
12. 12. Elg, S. A., A. R. Mayer, L. F. Carson, L. B. Twinggs, R. B. Hill, and S. Ramakrishnan. 1997. α-lacid glycoprotein is an immunosuppressive factor found in ascites from ovarian carcinoma. Cancer 80:1448.
13. 13. Scuderi, P., Dorr, R. T., Liddil, J. D., Finley, P. R., Meltzer, P., Raitano, A. B., and J. Rybski. 1989. Alpha-globulins suppress human leukocyte tumor necrosis factor secretion. Eur. J. Immunol. 19:939.
14. 14. Bories, P. N., J. Feger, N. Benbernou, J. D. Rouzeasu, J. Agneray, and G. Durand. 1990. Prevalence of tri- and tetraantennary glycans of human α1-acid glycoprotein in release of macrophage inhibitor of interleukin-1 activity. Inflammation 14:315.
15. 15. Pos, O., R. A. J. Ostendrop, M. E. Van Der Stelt, R. J. Scheper, and W. Van Dijk. 1990. Con A-nonreactive human α1-acid glycoprotein (AGP) is more effective in modulation of lymphocyte proliferation than con A-reactive AGP serum variants. Inflammation 14:133.
16. 16. Matsuno, S., M. Kobari, Y. Matsuda, and T. Sato. 1982. Diagnosis of carcinoma of the pancreas by assay of immunosuppressive acidic protein. Tohoku J. Exp. Med. 136:1.
17. 17. Sawada, M., Y. Okudaira, Y. Matsui, and Y. Shimizu. 1983. Immunosuppressive acidic protein in patients with ovarian cancer. Cancer 52:2081.
18. 18. Sawada, M., Y. Okudaira, Y. Matsui, and Y. Shimizu. 1984. Immunosuppressive acidic protein in patients with gynecologic cancer. Cancer 54:652.
19. 19. Tagawa, S., M. Sawada, Y. Tokumine, E. Ueda, T. Machi, S. Hayashi, Y. Kurata, and T. Kitami. 1985. Serum immunosuppressive acidic protein in adult T-cell leukemia (ATL). Scand. J. Hematol. 34:360.
20. 20. Tamura, K., Y. Shibata, Y. Matsuda, and N. Ishida. 1981. Isolation and characterization of an immunosuppressive acidic protein (IAP) from ascitic fluids of cancer patients. Cancer Res. 41:3244.
21. 21. Sibata, Y., K. Tamura, and N. Ishida. 1983. Analysis of the suppressive effects of immunosuppressive acidic protein, a type of α1-acidic protein, in connection with its high level in tumor-bearing mice. Cancer Res. 43:2889.
22. 22. Matsuno, S., T. Ejiri, M. Kabari, H. Yamauchi, and T. Sato. 1984. Effects of immunosuppressive acidic protein on DMBA-induced pancreatic cancer in rats. Tohoku J. Exp. Med. 144:189.
23. 23. Herberman, R. B. 1980. editor. In: Natural cell-mediated immunity against tumors. Academic Press, New York.
24. 24. Herberman, R. B. and J. R. Ortaldo. 1981. Natural killer cells: Their role in defenses against disease. Science 214:24.
25. 25. Herberman, R. B. 1982. editor. In: NK cells and other natural effector cells. Academic Press, New York.
26. 26. Aso, H., F. Suzuki, T. Ebina, and N. Ishida. 1989. Antiviral activity of carboxyethylgermanium sesquioxide (Ge-132) in mice infected with influenza virus. J. Biol. Response Mod. 8:180.
27. 27. Edwards, B. S., M. J. Hawkins, and E. C. Borden. 1984. Comparative and activation of human natural killer cells by two recombinant α-interferons differing in antiviral activity. Cancer Res. 44:3135.
28. 28. Svedersky, L. P., H. M. Shepard, S. A. Spencer, M. R. Shalaby, and M. A. Palladino. 1984. Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2. J. Immunol. 133:714.
29. 29. Trinchieri, G., M. Matsumoto-Kobayashi, S. C. Clark, J. Seehra, L. London, and B. Perussia. 1984. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med. 160:1147.
30. 30. Aso, H., K. Tamura, O. Yoshie, T. Nakamura, S. Kikuchi, and N. Ishida. 1992. Impaired NK response of cancer patients to IFN-a but not to IL-2: Correlation with serum immunosuppressive acidic protein (IAP) and role of suppressor macrophage. Microbiol. Immunol. 36:1087.
31. 31. Brunda, M. J., R. B. Herberman, and H. T. Holden. 1980. Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol. 124:2682.
32. 32. Droller, M. J., M. U. Schneider, and P. Perlmann. 1987. A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell. Immunol. 39:165.
33. 33. Okumura, Y., H. Ishibashi, M. Shirahama, S. Kurokawa, J. Kudo, H. Okubo, and Y. Niho. 1987. Kupffer cells modulate natural killer cell activity in vitro by producing proslaglandins. Cell. Immunol. 107:89.
34. 34. De Graaf, W. T., E. M. Van Der Stelt, G. M. Anbergen, and W. Van Dijk. 1993. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on α1-acid glycoprotein (orsomucoid) in human sera. J. Exp. Med. 177:657.